Sustainability Using Zero-Carbon Biopharma Facilities

The poster presentations contain data highlighting the company’s role to date in developing non-replicating HSV-1 technology for use in neurology.

This podcast explores the challenges of and the progress made so far by the biopharma industry toward alternative drug delivering methods for biologic drugs.

The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.

Hanns-Christian Mahler and Andrea Allmendinger from ten23 health will discuss some key aspects of biologic drug development and manufacturing.

Incorporating sustainable practices into process designs as early as possible ensures optimal performance.

The bio/pharma industry is evolving with intention, intelligence, and a growing sense of shared purpose.